PPG sets science-based 2030 decarbonization targets, reports 2022 sustainability progress
31.5.2023 17:15:00 EEST | Business Wire | Press release
PPG (NYSE:PPG) today announced its near-term 2030 sustainability goals, including greenhouse gas (GHG) emissions targets that have been validated by the Science Based Targets initiative (SBTi). The company also marked strong progress against its environmental, social and governance (ESG) priorities, reporting increased sales of sustainably advantaged products, more efficient operations, strong momentum towards achieving diversity, equity and inclusion goals, greater supplier sustainability and strengthened support within communities where the company operates.
“PPG has long been committed to reducing the environmental impact of its own operations, and we are proud to have validated science-based GHG emissions targets that are in line with the expectations of the Paris Agreement,” said Diane Kappas, PPG vice president, global sustainability. “By raising our sustainability ambitions and increasing sales of sustainable solutions for our customers, PPG is advancing its leadership in the paints and coatings industry.”
PPG has committed to reduce absolute emissions from its own operations (scope 1 and 2) by 50% by 2030 from a 2019 base year. It has also committed to reduce absolute scope 3 GHG emissions from purchased goods and services, processing of sold products, and end-of-life treatment of sold products by 30% within the same timeframe. The company’s emissions reduction strategy for its own operations includes energy efficiency projects and renewable energy sourcing. Within the value chain – or scope 3 – PPG is collaborating with suppliers to identify GHG emissions reduction opportunities and lower-carbon raw material sources. PPG recently signed an agreement with NRG Energy Inc. that will enable four PPG paints and coatings manufacturing facilities and 62 PPG PAINTS™ stores in Texas to operate on 100% renewable electricity.
In addition to its science-based emission targets, PPG’s other 2030 ESG targets against a 2019 baseline are:
- 50% of sales from sustainably advantaged products
- 15% reduction in water intensity at priority sites
- 25% reduction in waste intensity
- Reuse, recycle or recover 100% of process waste
- $5 million additional COLORFUL COMMUNITIES® funding, with each project incorporating an element of sustainability, making the total investment $15 million since 2015
- 100% of key suppliers assessed against sustainability and social responsibility criteria
- 100% of employees go home safely each day
- 5% annual reduction in spill and release rate
Furthermore, the company outlined key progress from the 2022 reporting year including:
- Developing sustainable innovations that meet customers’ greatest needs, such as the launch of PPG INNOVEL® PRO, a non-bisphenol/non-BPA coating that ensures minimal spoilage and protection for aluminum beverage cans, while promoting circularity.
- Collaborating with Steelcase, a U.S. manufacturer of architecture, furniture and technology products, to further increase the circularity of PPG powder coatings. PPG developed processes to recycle powder overspray into new coatings, which Steelcase uses on brackets, inside drawers and other less-visible surfaces in its products.
- Continued investment in PPG’s signature Colorful Communities initiative. The company marked more than 470 projects, impacting more than 8 million people since 2015.
-
Strong improvement against 2025 diversity, equity and inclusion aspirational goals, including:
- 19% increase in U.S. non-frontline Black headcount
- 16% increase in U.S. non-frontline Latino headcount
- 8% increase in U.S. non-frontline Asian headcount
- 31% representation of non-frontline female professionals; a 180 basis-point improvement from 2021
“We remain committed to our journey of fostering a more diverse and inclusive community both within and beyond PPG,” said Marvin Mendoza, PPG global head, diversity, equity and inclusion. “We know that diverse teams perform better, and our 2022 progress is enabling a more equitable, inclusive future where employees feel even more empowered to bring their whole selves to work.”
Additional 2022 progress is outlined in further detail in PPG’s just-released 2022 Environmental, Social and Governance (ESG) Report at ppg.com/sustainability.
The Science Based Targets initiative (SBTi) mobilizes companies to set science-based targets and boost their competitive advantage in the transition to the low-carbon economy. It is a partnership between CDP, the United Nations Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF). The SBTi call to action is one of the We Mean Business Coalition commitments. The initiative defines and promotes best practice in science-based target setting, offers resources and guidance to reduce barriers to adoption, and independently assesses and approves companies’ targets.
PPG: WE PROTECT AND BEAUTIFY THE WORLD®
At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and specialty materials that our customers have trusted for 140 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 70 countries and reported net sales of $17.7 billion in 2022. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com.
PPG Paints is a trademark and Colorful Communities, Innovel, the PPG Logo and We protect and beautify the world are registered trademarks of PPG Industries Ohio, Inc.
CATEGORY Sustainability
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230531005110/en/
Contact information
Greta Edgar Borza
Corporate Communications
+1 724 316 7552
edgar@ppg.com
www.ppg.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
